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Journal of Clinical & Translational Endocrinology 1 (2014) 167–169EditorialThe role of vitamin D in tuberculosisqVitamin D deﬁciency is associated with the risk of tuberculosis
(TB) infection [1,2]. Vitamin D deﬁcient individuals have a greater
susceptibility to developing TB [3] and worse disease progression
if infected with TB [4,5]. The likely mechanism through which
vitamin D may prevent or limit infection by Mycobacterium Tuber-
culosis is through the binding of the bioactive form of vitamin D
(1,25-dihydroxycholecalciferol) to the vitamin D receptor (VDR), a
polymorphic nuclear receptor that regulates the expression of
genes important for immune function and involved in cytokine pro-
duction [6–8]. The VDR is present in immune cells [9,10] and bron-
chial and pulmonary epithelial cells [11,12], and is up-regulated
following the ligation of speciﬁc toll-like receptors (TLRs) during
an antimicrobial response [13,14]. Through this mechanism, calci-
triol induces several endogenous antimicrobial peptides [15,16],
speciﬁcally cathelicidin LL-37 and b defensin [13,16], and sup-
presses matrix metalloproteinase enzymes that degrade the pul-
monary extracellular matrix [17].
Though vitamin D was used to treat TB during the pre-antibiotic
era, trials in recent years have continued to assess its role in the treat-
ment and prevention of TB. A systematic review published this
month in the Journal of Clinical and Translational Endocrinology by
Sutaria et al. [18] evaluated the results from 21 randomized,
controlled trials in order to assess: the relationship between low
vitamin D status and TB, the link between VDR polymorphisms and
TB susceptibility, and the role of vitamin D supplementation in TB
treatment and prevention. Sutaria et al. concluded that: 1) individuals
with TB had lower vitamin D status (lower serum levels of 25(OH)D
[19]) than healthy, age-matched, and sex-matched controls, 2) people
with certain VDR polymorphisms (BsmI and FokI) had increased sus-
ceptibility to TB, and 3) TB patients receiving vitamin D supplemen-
tation had improved outcomes in a majority of studies [18].
Similar to Sutaria et al. [18], our recent systematic review
regarding vitamin D supplementation in infectious disease [20]
found 9 of 11 prospective, controlled trials in TB patients to have at
least 1 positive outcome in response to vitamin D therapy. Vitamin
D supplements promoted anti-mycobacterial activity [21], improved
clinical outcomes (improved weight gain [22,23] and decreased tis-
sue involvement on imaging studies [22,23]), increased sputum
smear and culture conversion [24,25], reduced inﬂammation [26],
and increased mediators of anti-microbial activity (cathelicidin LL-
37 [27] and IFN-g [22]). However, these results were not necessarily
primaryendpoints in their respective studiesor applicableoutsideof
speciﬁc subgroups. Furthermore, other studies had negative resultsDOI of original article: http://dx.doi.org/10.1016/j.jcte.2014.08.001.
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Open access under CC BY-NC-ND license.formanyof the sameendpoints, including no change to clinicalmea-
sures (X-ray involvement [23,24,28], clinical severity scores [29] and
weight gain [29]), IFN-g transcription [21] and sputum smear and
culture conversion [25,28–30].
The inconsistent results in these studies make it difﬁcult to draw
a unifying conclusion on vitamin D in TB treatment. Many factors,
including those inherent to the studies themselves, in addition to
those that impact study participants’ response to vitamin D and
vitamin D status, may obscure a relationship between vitamin D
and TB. Primarily, these trials are limited by their inability to eval-
uate vitamin D alone as treatment for TB, as it would be unethical to
withhold established antibiotic therapy from study participants. In
addition, the dose and duration of vitamin D treatment necessary to
optimize infectious outcomes is currently unknown, leading to high
variability between the dose (20,000 IU [27] to 1,200,000 IU [22]
cumulative doses), dosing interval (days [23,24,27,31] to months
[22,28,29]) and vitamin D formulation (1 study used vitamin D2
[21] and 2 did not publish the formulation [23,24]). Some of these
strategies may have been sub-optimal, such as daily dosing strate-
gies (large clinical trials have shown poor adherence to daily doses
[32,33]) and the use of vitamin D2, which is less effective at
increasing serum 25(OH)D than vitamin D3 at similar doses [34,35].
Beyond the variability inherent to the studies themselves, there
is a wide variation in individual responses to vitamin D supple-
mentation on 25(OH)D concentration [36,37]. Since the anti-
mycobacterial response mediated by TLRs in macrophages is
strongly dependent on 25(OH)D concentration [13], characteristics
that inﬂuence the change in vitamin D status following supplemen-
tation, including baseline 25-hydroxyvitamin D (25(OH)D) concen-
tration [38] and genetic polymorphisms of the vitamin D binding
protein (DBP) [39] and VDR [40], could also inﬂuence the effects
of vitamin D supplementation on TB infection in certain individuals.
For one, baseline 25(OH)D concentration, the key measure of
vitamin D status [19], is inversely linked to the response to vitamin D
administration [35,41]; vitamin D sufﬁcient individuals achieve a
lesser increase in 25(OH)D concentration with supplementation
compared to deﬁcient individuals [38]. Individuals who are more
vitaminDsufﬁcient thanothers inastudypopulation,duetovariations
in factors that impact vitamin D status (time outdoors [42], body
habitus [43], skin pigment [44], etc.), may have a blunted vitamin D
response and change to infectious outcomes in some studies. The im-
plicationsof thisobservationwereseen inSalahuddinetal. [22],where
only the vitamin D deﬁcient subset of study participants experienced
signiﬁcant increases in IFN-g production following vitamin D admin-
istration. This may also explain the negative results in Wejse et al.
[29], the only study with a mean baseline 25(OH)D concentration
>30 ng/mL. Alternatively, as suggested by Heaney [45], a physiologic
response following vitamin D supplementation would only occur if
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iologic effects occur. Thus, studiesmay not demonstrate improvement
following vitaminD supplementation if participants’ baseline vitamin
D status falls outside the range inwhicheffects on infectious outcomes
are seen.
The vitamin D binding protein (DBP) is another major determi-
nant to the free and total circulating 25(OH)D concentration [46];
it binds 85–90% of the 25(OH)D in circulation [47], increases the
half-life of 25(OH)D as a vitamin D reservoir in circulation, and
aids in reabsorbing vitamin D ﬁltered in the kidney [48,49]. The
race- and genetic-dependent variations in the DBP [50,51] center
around 2 single nucleotide polymorphisms (SNPs) in the globulin-
complex (Gc) gene [52] that have different afﬁnities for binding
25(OH)D [53]. Thus, certain variants of the DBP may prolong the
half-life of vitamin D in circulation more than others [54] and play
a role in preventing vitamin D deﬁciency [55]. Furthermore, studies
suggest that free or bio-available 25(OH)D (vitamin D not bound to
DBP) is more reﬂective of true vitamin D status than total 25(OH)
D, the typical measure of vitamin D status [56]; bio-available
25(OH)D concentrations signiﬁcantly correlate with bone mineral
density [57,58] and parathyroid hormone levels [59] while total
25(OH)D does not [57–59]. Measuring bio-available 25(OH)D and
evaluating DBP polymorphisms may thus be necessary to reassess
vitamin D status following vitamin D administration in infectious
disease. Although not extensively studied in infectious disease, 1
study found Gc genotype to be associated with susceptibility to TB
[60] while 2 others found DBP variants to impact outcomes in rheu-
matic fever [61] and human immunodeﬁciency virus (HIV) [62].
While these observations may be due to the impact of DBP variants
on vitamin D status, DBP also appears to have a direct impact im-
mune function, attenuating the effect of complement factor C5a, a
chemotactic protein [63], and stimulating macrophage activity [64].
Variants of theVDRhave alsobeen found to affect vitaminD status
[46,65], in addition to susceptibility to TB [66–68]. The ethnicity- and
geography-dependent susceptibility and resistance patterns to TB
appear to be linked to thevaryingprevalence of these polymorphisms
indifferentpopulations [18]. Though thesepolymorphismshavebeen
analyzed in relatively fewstudies, includingonlyone prospective trial
of vitamin D administration in TB [25], the VDR polymorphism ap-
pears to affect the efﬁcacy of the vitamin D administered; Martineau
et al. [25]onlyobserveda signiﬁcantlyacceleratedsputumconversion
rate inTB patients receiving vitaminD supplementationwhenpartic-
ipants were stratiﬁed based on genotype of the TaqI polymorphism.
Thus, not accounting for VDR variations in other studies may have
masked the impact of vitamin D on TB.
Overall, future research on vitamin D supplementation will
likely need to account for factors that contribute to variations in
response to vitamin D supplementation. Better assessment of
vitamin D status by measuring bio-available or free vitamin D in
addition to vitamin D binding protein may add more information
in determining vitamin D status of subjects. Classiﬁcation of sub-
jects by genotype variations in the vitamin D axis would also be
of interest. However, determining these genetic variants may
currently be impractical for clinical care or research due to cost.
Stratifying future study populations by characteristics such as
race, age, health status, baseline vitamin D status, and skin pigment
in order to create a cohort with a more homogenous response to
vitamin D supplementationmay be necessary in order to determine
effective dosing strategies and to observe a clearer association be-
tween vitamin D and infectious diseases like TB.Malcolm D. Kearns, BS
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